Clinical Trial Update: AZAHAR Study To Describe Anifrolumab in a Real-World Setting

View source ↗

Summary

An observational real-world study update detailing the use of Anifrolumab in systemic lupus erythematosus (SLE) from the AZAHAR study. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus (SLE) | Status: COMPLETED